Trial shows trastuzumab should remain as standard of care for HER2-positive breast cancer

Data from worldwide trial of two HER2-positive breast cancer drugs

2014-09-29

(Press-News.org) JACKSONVILLE, Fla., Sept. 29, 2014 — Analysis of more than 8,000 women who participated in the world's largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab (Herceptin) should remain the standard of care for this cancer, says a Mayo Clinic researcher.

This study, being presented at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, reveals that when used as a single HER2-targeted therapy in addition to standard chemotherapy, trastuzumab offers a better outcome than does lapatinib (Tykerb), says Edith A. Perez, M.D., deputy director at large, Mayo Clinic Cancer Center and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida.

Dr. Perez is co-chair of ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization study). The phase III clinical trial, which tested combinations of the two drugs or use of the drugs by themselves — in addition to standard chemotherapy — enrolled 8,381 participants at 946 medical centers in 44 countries.

A key finding from ALTTO, released in June, showed that lapatinib, when used in addition to trastuzumab as part of dual therapy, did not offer any statistically significant benefit to patients, such as disease-free survival or overall survival. Dual blockade using two anti-HER2 drugs only increased toxicity, said Dr. Perez.

This new analysis compared use of lapatinib or trastuzumab alone, as well as outcome in disease-free patients who were offered trastuzumab as adjuvant treatment after being treated with lapatinib alone.

The researchers found that trastuzumab offered a better outcome compared to use of lapatinib alone. After 4.5 years of follow-up, 14 percent of patients using trastuzumab experienced at least one disease event, compared to 18 percent of patients using lapatinib. A disease event is defined as breast cancer recurrence anywhere in the body, a new cancer, or death of any cause.

However, cardiac safety was good in both groups, and there was no difference in the rate of development of brain metastasis, says Dr. Perez.

The researchers also showed that switching from lapatinib to trastuzumab offered a benefit to patients. Of the 2,100 patients in the lapatinib arm, 52 percent received at least one dose of trastuzumab.

"We were glad that we received early notice in August 2011 of the potential lower benefit of lapatinib versus trastuzumab, which led us to offer trastuzumab for the patients who had been assigned to lapatinib alone. This intervention speaks well to our flexibility in the conduct of clinical trials," says Dr. Perez.

"ALTTO was and is a very important global trial. All patients were carefully managed and we demonstrated better overall outcomes than anticipated," she says. "We demonstrated that lapatinib's activity appeared to be lower than that of trastuzumab in the adjuvant setting, that there was a trend for additional benefit if those patients were switched to trastuzumab, that cardiac safety was better than predicted, and that the number of brain metastases appeared similar for the patients who received either lapatinib or trastuzumab."

Dr. Perez adds that patients are still being followed, and the research team is investigating tumor and blood specimens to discover and analyze potential biomarkers for treatment efficacy.

INFORMATION: The study was funded by The Breast Cancer Intergroup of North America (TBCI), based in the United States, the Breast International Group (BIG) in Brussels, Belgium, the National Cancer Institute and Glaxo SmithKline. TBCI consists of six NCI-funded clinical trials cooperative groups. NCI is part of the National Institutes of Health.

About Mayo Clinic Recognizing 150 years of serving humanity in 2014, Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit 150years.mayoclinic.org, MayoClinic.org or newsnetwork.mayoclinic.org.

About Mayo Clinic Cancer Center As a leading institution funded by the National Cancer Institute, Mayo Clinic Cancer Center conducts basic, clinical and population science research, translating discoveries into improved methods for prevention, diagnosis, prognosis and therapy. For information on cancer clinical trials, call 507-538-7623.

ELSE PRESS RELEASES FROM THIS DATE:

Tooth serves as evidence of 220 million-year-old attack

2014-09-29

At the beginning of the age of dinosaurs, gigantic reptiles—distant relatives of modern crocodiles—ruled the earth. Some lived on land and others in water and it was thought they didn't much interact. But a tooth found by a University of Tennessee, Knoxville, researcher in the thigh of one of these ancient animals is challenging this belief. Stephanie Drumheller, an earth and planetary sciences lecturer, and her Virginia Tech colleagues Michelle Stocker and Sterling Nesbitt examined 220-million-year-old bite marks in the thigh bones of an old reptile and found evidence ...

A molecular mechanism involved in cellular proliferation characterized

2014-09-29

Researchers from Guillermo Montoya's team at the Spanish National Cancer Research Centre (CNIO), in collaboration with Isabelle Vernos' Group from the Centre for Genomic Regulation (CRG), have uncovered the molecular interaction between TACC3 and chTOG, key proteins in forming the internal cellular framework that enables and sustains cell division. Published today in Nature Communications, the observations may help to optimise current oncological therapies specifically designed to fight against this framework, named by the scientific community as microtubules. KEY MOLECULES ...

New method to motivate students to reduce energy consumption

2014-09-29

The research found that a combination of a real-time feedback system together with a human energy delegate in eight halls of residence resulted in a reduction of 37% in energy consumption when compared to normal consumption. The savings were 1360.49 kWh, which is equivalent to a reduction of 713.71 kg of CO2 over four weeks. In contrast, another eight halls, exposed only to the real-time feedback and a weekly email alert, resulted in saw a 3.5% reduction in energy consumption. Student's energy-use behaviour is complex as they cannot easily identify how much electricity ...

Dolphins are attracted to magnets

2014-09-29

Dolphins are indeed sensitive to magnetic stimuli, as they behave differently when swimming near magnetized objects. So says Dorothee Kremers and her colleagues at Ethos unit of the Université de Rennes in France, in a study in Springer's journal Naturwissenschaften – The Science of Nature. Their research, conducted in the delphinarium of Planète Sauvage in France, provides experimental behavioral proof that these marine animals are magnetoreceptive. Magnetoreception implies the ability to perceive a magnetic field. It is supposed to play an important role in how some ...

Human trafficking, an invisible problem

2014-09-29

This news release is available in Spanish. This study compares the existing legislation on this subject in European countries and analyzes both the level of protection afforded to the victims and the measures taken to avoid this crime; in addition, it proposes of code of best practices that favors the enactment of new European guidelines aimed at ending this activity. Specifically, it shows that one of the first obstacles to change is that the magnitude of the problem is not known, points out one of the authors of the report, Begoña Marugán Pintos, of the department ...

Evolutionary biology: It's not just for textbooks anymore

2014-09-29

Solving global challenges in food security, emerging diseases and biodiversity loss requires evolutionary thinking, argues a new study published online in Science Express that was co-authored by Bruce Tabashnik of the University of Arizona College of Agriculture and Life Sciences. For the first time, an international team of nine scientists has reviewed progress in addressing a broad set of challenges in agriculture, medicine and environmental management using approaches that consider evolutionary histories and the likelihood of rapid adaptation to human activities. The ...

IMPRESS trial data on continuing tyrosine kinase inhibitor therapy after resistance development in lung cancer reported

2014-09-29

Patients whose lung cancer has developed resistance to the drug gefitinib experience no statistically significant improvement in progression-free survival from continued treatment with the drug in addition to chemotherapy, a phase III trial presented at the ESMO 2014 Congress has shown. The IMPRESS trial is a randomised phase III study that compared continuation of gefitinib in addition to chemotherapy against chemotherapy alone in patients with lung cancer that carried mutations in the EGFR cell surface receptor. Gefitinib is a type of drug known as a tyrosine kinase ...

Pertuzumab adds 16 months survival benefit to trastuzumab and chemo treatment for HER2-positive breast cancer

2014-09-29

Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy compared to those treated with trastuzumab and chemotherapy alone, updated results from the CLEOPATRA study reveal. CLEOPATRA was a pivotal phase III study where researchers evaluated the safety and efficacy of pertuzumab, trastuzumb and chemotherapy in 808 patients with previously untreated HER2-positive metastatic breast cancer. HER2-positive metastatic breast cancer has historically ...

Adding cediranib to chemo improves progression-free survival for meta or recurrent cervical cancer

2014-09-29

For patients with cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression-free survival, researchers report at the ESMO 2014 Congress in Madrid. In Europe, about 70% of patients with cervical cancer are cured by either surgery or chemo-radiotherapy. Those patients with recurrent or secondary cancer have a very poor outlook. Only about 20-30% have tumour shrinkage after conventional chemotherapy and survival ...

Many patients lack information about the use of targeted therapies, oncologists say

2014-09-29

More than three quarters of oncology specialists in Europe, South America and Asia believe their patients are not always well enough informed about the treatment options available to them, survey results have revealed at the ESMO 2014 Congress in Madrid, Spain. The results come from an online survey of 895 doctors from 12 countries in Europe, South America and Asia. All were practicing oncology specialists, with more than three years' experience, treating more than fifteen patients a month. While 82% of those surveyed believed that deciding on a course of treatment ...

Innovative risk score accurately calculates which kidney transplant candidates are also at risk for heart attack or stroke, new study finds

Amid record year for dengue infections, new study finds climate change responsible for 19% of today’s rising dengue burden

New study finds air pollution increases inflammation primarily in patients with heart disease

AI finds undiagnosed liver disease in early stages

The American Society of Tropical Medicine and Hygiene and the Bill & Melinda Gates Foundation announce new research fellowship in malaria genomics in honor of professor Dominic Kwiatkowski

Trial shows trastuzumab should remain as standard of care for HER2-positive breast cancer

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: